Bristol-Myers Co.

Packaging Products & Equipment

Bristol Leads the Way

Chesapeake Bristol is the first self-adhesive label manufacturer in the UK to introduce an ultra-low migration (ULM) ink system as standard for all its customers. The move to ULM-only ink follows extensive trials and rigorous testing procedures. The Bristol operation is Chesapeake's lead label site in the UK for food labelling and this initiative offers customers further reassurance that they are...

Read More »
Packaging Products & Equipment

Bristol Leads the Way

Chesapeake Bristol is the first self-adhesive label manufacturer in the UK to introduce an ultra-low migration (ULM) ink system as standard for all its customers. The move to ULM-only ink follows extensive trials and rigorous testing procedures. The Bristol operation is Chesapeake's lead label site in the UK for food labelling and this initiative offers customers further reassurance that they are...

Read More »
Mergers & Acquisitions

Bristol-Myers Squibb to Acquire Adnexus Therapeutics

Bristol-Myers Squibb to Advance Biologics Strategy Through Targeted Biologics Acquisition PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 -- Bristol-Myers Squibb Company (NYSE:BMY) and Adnexus(TM) Therapeutics announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of...

Read More »
Company News

Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes

PRINCETON, N.J. and WHITEHOUSE STATION, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) jointly announced today that the U.S. Food and Drug Administration (FDA) issued an approvable letter for PARGLUVA(TM) (muraglitazar), the companies' investigational oral medicine for the treatment of type 2 diabetes. The FDA has requested...

Read More »

All Topics